LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Kwok, Chun Shing; Krupa, Lukasz; Mahtani, Ash; Kaye, Duncan; Rushbrook, Simon M.; Phillips, Martin G.; Gelson, William (2013)
Publisher: Hindawi Publishing Corporation
Journal: BioMed Research International
Languages: English
Types: Article
Subjects: Review Article, R, Medicine, Article Subject, R1
Background. Studies have suggested that albumin has a value in cirrhotic patients undergoing paracentesis but its value in infection and sepsis is less clear. We planned to perform a meta-analysis of the risk of adverse outcomes in cirrhotic patients with and without albumin use. Methods. We searched MEDLINE and EMBASE in January 2013 for randomized studies of cirrhotic patients that reported the risk of adverse events and mortality with albumin and no albumin exposure. We performed random effects meta-analysis and assessed heterogeneity using the I2 statistic. Results. Our review included 16 studies covering 1,518 patients. The use of albumin in paracentesis was associated with significantly reduced risk of paracentesis-induced circulatory dysfunction (OR 0.26 95%, CI 0.08–0.93) and there was a nonsignificant difference in death, encephalopathy, hyponatraemia, readmission, and renal impairment. Compared to the other volume expanders, albumin use showed no difference in clinical outcomes. In cirrhotic patients with any infection, there was a significant reduction in mortality (OR 0.46 95%, CI 0.25–0.86) and renal impairment (OR 0.34 95%, CI 0.15–0.75) when albumin was used. Conclusion. The use of albumin in cirrhotic patients is valuable in patients with any infection and it reduces the risk of circulatory dysfunction among patients undergoing paracentesis.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] L. Ruiz-Del-Arbol, A. Monescillo, W. Jimenez, A. Garcia-Plaza, V. Arroyo, and J. Rodes, “Paracentesis-induced circulatory dysfunction: mechanism and eefct on hepatic hemodynamics in cirrhosis,” Gastroenterology, vol. 113, no. 2, pp. 579-586, 1997.
    • [2] P. Gines, L. Tito, V. Arroyo et al., “Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis,” Gastroenterology, vol. 94, no. 6, pp. 1493- 1502, 1988.
    • [3] P. Gine`s and A. Ca´rdenas, “eTh management of ascites and hyponatremia in cirrhosis,” Seminars in Liver Disease, vol. 28, no. 1, pp. 43-58, 2008.
    • [4] F. Salerno, M. Guevara, M. Bernardi et al., “Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis,” Liver International, vol. 30, no. 7, pp. 937-947, 2010.
    • [5] B. A. Runyon, “Management of adult patients with ascites due to cirrhosis: update 2012,” AASLD Practice Guidelines. http://www.aasld.org/practiceguidelines/Documents/ascitesupdate2013.pdf.
    • [6] P. Gine`s, P. Angeli, K. Lenz et al., “EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis,” Journal of Hepatology, vol. 53, no. 3, pp. 397-417, 2010.
    • [7] J. Ferna´ndez, M. Navasa, J. C. Garcia-Pagan et al., “Eefct of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis,” Journal of Hepatology, vol. 41, no. 3, pp. 384-390, 2004.
    • [8] P. Sort, M. Navasa, V. Arroyo et al., “Eefct of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis,” eTh New England Journal of Medicine, vol. 341, no. 6, pp. 403-409, 1999.
    • [9] J. Ferna´ndez, M. Navasa, J. Go´mez et al., “Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and noroflxacin prophylaxis,” Hepatology, vol. 35, no. 1, pp. 140- 148, 2002.
    • [10] F. Wong, M. Bernardi, R. Balk et al., “Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club,” Gut, vol. 54, no. 5, pp. 718-725, 2005.
    • [11] P. Tandon and G. Garcia-Tsao, “Bacterial infections, sepsis, and multiorgan failure in cirrhosis,” Seminars in Liver Disease, vol. 28, no. 1, pp. 26-42, 2008.
    • [12] V. Arvaniti, G. D'Amico, G. Fede et al., “Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis,” Gastroenterology, vol. 139, no. 4, pp. 1246-1256, 2010.
    • [13] A. Follo, J. M. Llovet, M. Navasa et al., “Renal impairment aeftr spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis,” Hepatology, vol. 20, no. 6, pp. 1495-1501, 1994.
    • [14] T. Gustot, F. Durand, D. Lebrec, J.-L. Vincent, and R. Moreau, “Severe sepsis in cirrhosis,” Hepatology, vol. 50, no. 6, pp. 2022- 2033, 2009.
    • [15] B. A. Runyon, “Albumin infusion for spontaneous bacterial peritonitis,” eTh Lancet , vol. 354, no. 9193, pp. 1838-1839, 1999.
    • [16] P. Tandon and G. Garcia-Tsao, “Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis,” Clinical Gastroenterology and Hepatology, vol. 9, no. 3, pp. 260-265, 2011.
    • [17] M. Guevara, V. Arroyo, and P. Gines, “Eefct of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. eTh question remains open,” Journal of Hepatology, vol. 58, no. 3, pp. 640-649, 2013.
    • [18] http://hiru.mcmaster.ca/hiru/HIRU Hedges EMBASE Strategies.aspx, and, http://hiru.mcmaster.ca/hiru/HIRU Hedges MEDLINE Strategies.aspx.
    • [19] E. E. Abdel-Khalek and S. E. Arif, “Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis,” Arab Journal of Gastroenterology, vol. 11, no. 1, pp. 24-29, 2010.
    • [20] C. Altman, B. Bernard, D. Roulot, R.-L. Vitte, and O. Ink, “Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis,” European Journal of Gastroenterology and Hepatology, vol. 10, no. 1, pp. 5-10, 1998.
    • [21] C. H. Choi, K. H. Han, D. Y. Kim et al., “Eficacy and safety of large volume paracentesis in cirrhotic patients with spontaneous bacterial peritonitis: a randomized prospective study,” eTh Korean Journal of Hepatology , vol. 8, no. 1, pp. 52- 60, 2002.
    • [22] E. Fassio, R. Terg, G. Landeira et al., “Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study,” Journal of Hepatology, vol. 14, no. 2-3, pp. 310-316, 1992.
    • [23] D. Garcia-Compean, J. Z. Villarreal, H. B. Cuevas et al., “Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial,” Liver, vol. 13, no. 5, pp. 233-238, 1993.
    • [24] D. Garc´ıa-Compean, P. Blanc, D. Larrey et al., “Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial,” Annals of Hepatology, vol. 1, no. 1, pp. 29-35, 2002.
    • [25] A. Gines, G. Fernandez-Esparrach, A. Monescillo et al., “Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis,” Gastroenterology, vol. 111, no. 4, pp. 1002-1010, 1996.
    • [26] M. Guevara, C. Terra, A. Nazar, E. Sola, J. Fernandez, M. Pavesi et al., “Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study,” Journal of Hepatology, vol. 57, no. 4, pp. 759-765, 2012.
    • [27] R. Moreau, D.-C. Valla, I. Durand-Zaleski et al., “Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial,” Liver International, vol. 26, no. 1, pp. 46- 54, 2006.
    • [28] A. Nazar, M. Guevara, C. Terra, M. Martin-Llahi, M. E. Baccaro, M. Pavesi et al., “Eefct of albumin administration in patients with cirrhosis and bacterial infection other than spontaneous bacterial peritonitis. A randomized controlled study,” Journal of Hepatology, vol. 50, p. S86, 2009.
    • [29] R. Planas, P. Gines, V. Arroyo et al., “Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis: Results of a randomized study,” Gastroenterology, vol. 99, no. 6, pp. 1736-1744, 1990.
    • [30] J. Sola-Vera, J. Min˜ana, E. Ricart et al., “Randomized trial comparing albumin and saline in the prevention of paracentesisinduced circulatory dysfunction in cirrhotic patients with ascites,” Hepatology, vol. 37, no. 5, pp. 1147-1153, 2003.
    • [31] H. P. Xue, B. Lin, J. Z. Mo, and J. Q. Li, “Eefct of albumin infusion on preventing the deterioration of renal function in patients with spontaneous bacterial peritonitis,” Chinese Journal of Digestive Diseases, vol. 3, no. 1, pp. 32-34, 2002.
    • [32] J. P. T. Higgins and S. Green, Cochrane Handbook For Systematic Reviews of Interventions Version 5.0.2, eTh Cochrane Collaboration, 2009, www.cochrane-handbook.org .
    • [33] J. P. T. Higgins, S. G. oThmpson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557-560, 2003.
    • [34] R. Moreau, D.-C. Valla, I. Durand-Zaleski et al., “Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial,” Liver International, vol. 26, no. 1, pp. 46- 54, 2006.
    • [35] F. Salerno, S. Badalamenti, E. Lorenzano, P. Moser, and P. Incerti, “Randomized comparative study of hemaccel vs. albumin infusion aeftr total paracentesis in cirrhotic patients with refractory ascites,” Hepatology, vol. 13, no. 4, pp. 707-713, 1991.
    • [36] M. Bernardi, P. Caraceni, R. J. Navickis, and M. M. Wilkes, “Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials,” Hepatology, vol. 55, no. 4, pp. 1172-1181, 2012.
    • ology Volume 2014 Journal of Hindawi Publishing Corporation ht p:/ www.hindawi.com
  • No related research data.
  • No similar publications.